Figure 6
Changes in axon transport are accompanied by increased expression of phosphorylated p38 MAPK and downstream Hsp27, but not Tau. (a) Immunolocalization of phosphorylated p38 MAPK (p-p38 MAPK; magenta), in retinas from the 48-h post-CTB injection transport studies, revealed increased expression in eyes treated with sVEGFR-2 (right panels), in comparison with IgG1 controls (left panels). Original magnification= × 10; green=CTB, blue=DAPI. Higher magnification ( × 40) images (left middle and right) showing elevated p-p38 MAPK as well as nuclear localization in some cells (arrows) in sVEGFR-2 treated retinas. (b) Differences in expression of phosphorylated Hsp27 were also observed between IgG1 (left panels) and sVEGFR-2 (left panels) treatment. Phosphorylated Hsp27 (green) was strongly upregulated following sVEGFR-2 administration, and colocalized with GFAP (red),41 indicating astrocyte expression. Blue=DAPI. Left and right middle panels – original magnification= × 10; left middle and right panels – original magnification= × 40. (c) In contrast, no changes were detected in phosphorylated Tau levels between IgG1 (left panels) and sVEGFR-2 (right panels). Red=p-Tau, green=CTB, blue=DAPI. Original magnifications= × 10 (left and right middle) and × 40 (left middle and right)
